Trial Profile

A clinical study of ANAVEX®2-73 (blarcamesine) for the disease modifying treatment of Parkinson's disease

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Aug 2020 New trial record
19 Aug 2020 According to an Anavex Life Sciences media release, all patients who participate in the study will be eligible to receive ANAVEX 2-73 (blarcamesine) under a voluntary open label extension protocol.
19 Aug 2020 According to an Anavex Life Sciences media release, the planned clinical study will use a convenient, once-daily oral ANAVEX 2-73 formulation to confirm the previously established disease modifying features of ANAVEX 2-73 in an animal model of Parkinson's disease. Safety and efficacy will be investigated in an appropriately powered placebo-controlled clinical study of Parkinson's disease patients over at least 48-weeks including ANAVEX 2-73-specific precision medicine biomarkers.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com